Literature DB >> 28237205

Value Assessment Frameworks for HTA Agencies: The Organization of Evidence-Informed Deliberative Processes.

Rob Baltussen1, Maarten Paul Maria Jansen2, Leon Bijlmakers2, Janneke Grutters2, Anouck Kluytmans2, Rob P Reuzel2, Marcia Tummers2, Gert Jan van der Wilt2.   

Abstract

Priority setting in health care has been long recognized as an intrinsically complex and value-laden process. Yet, health technology assessment agencies (HTAs) presently employ value assessment frameworks that are ill fitted to capture the range and diversity of stakeholder values and thereby risk compromising the legitimacy of their recommendations. We propose "evidence-informed deliberative processes" as an alternative framework with the aim to enhance this legitimacy. This framework integrates two increasingly popular and complementary frameworks for priority setting: multicriteria decision analysis and accountability for reasonableness. Evidence-informed deliberative processes are, on one hand, based on early, continued stakeholder deliberation to learn about the importance of relevant social values. On the other hand, they are based on rational decision-making through evidence-informed evaluation of the identified values. The framework has important implications for how HTA agencies should ideally organize their processes. First, HTA agencies should take the responsibility of organizing stakeholder involvement. Second, agencies are advised to integrate their assessment and appraisal phases, allowing for the timely collection of evidence on values that are considered relevant. Third, HTA agencies should subject their decision-making criteria to public scrutiny. Fourth, agencies are advised to use a checklist of potentially relevant criteria and to provide argumentation for how each criterion affected the recommendation. Fifth, HTA agencies must publish their argumentation and install options for appeal. The framework should not be considered a blueprint for HTA agencies but rather an aspirational goal-agencies can take incremental steps toward achieving this goal.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Evidence-informed deliberative processes; HTA agency; Health Technology Assessment; Value Assessment Framework

Mesh:

Year:  2017        PMID: 28237205     DOI: 10.1016/j.jval.2016.11.019

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  31 in total

1.  Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review.

Authors:  Alexander Moreno-Calderón; Thai S Tong; Praveen Thokala
Journal:  Pharmacoeconomics       Date:  2020-03       Impact factor: 4.981

2.  Deliberative Processes by Health Technology Assessment Agencies: A Reflection on Legitimacy, Values and Patient and Public Involvement Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".

Authors:  Mireille Goetghebeur; Marjo Cellier
Journal:  Int J Health Policy Manag       Date:  2021-03-14

3.  Public values and plurality in health priority setting: What to do when people disagree and why we should care about reasons as well as choices.

Authors:  Rachel Baker; Helen Mason; Neil McHugh; Cam Donaldson
Journal:  Soc Sci Med       Date:  2021-04-02       Impact factor: 4.634

4.  Progressive Realisation of Universal Health Coverage in Low- and Middle-Income Countries: Beyond the "Best Buys".

Authors:  Melanie Y Bertram; Jeremy A Lauer; Karin Stenberg; Ambinintsoa H Ralaidovy; Tessa Tan-Torres Edejer
Journal:  Int J Health Policy Manag       Date:  2021-11-01

5.  Introduction to the Special Issue on "The World Health Organization Choosing Interventions That Are Cost-Effective (WHO-CHOICE) Update".

Authors:  Melanie Y Bertram; Tessa Tan Torres Edejer
Journal:  Int J Health Policy Manag       Date:  2021-11-01

6.  Evidence-Informed Deliberative Processes - Early Dialogue, Broad Focus and Relevance: A Response to Recent Commentaries.

Authors:  Maarten P Jansen; Rob Baltussen; Evelinn Mikkelsen; Noor Tromp; Jan Hontelez; Leon Bijlmakers; Gert Jan van der Wilt
Journal:  Int J Health Policy Manag       Date:  2018-01-01

7.  Realizing Universal Health Coverage in East Africa: the relevance of human rights.

Authors:  Alicia Ely Yamin; Allan Maleche
Journal:  BMC Int Health Hum Rights       Date:  2017-08-03

8.  Balanced assessment systems revisited.

Authors:  Dávid Dankó; Márk Péter Molnár
Journal:  J Mark Access Health Policy       Date:  2017-07-26

9.  Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis.

Authors:  Néboa Zozaya; Lucía Martínez-Galdeano; Bleric Alcalá; Jose Carlos Armario-Hita; Concepción Carmona; Jose Manuel Carrascosa; Pedro Herranz; María Jesús Lamas; Marta Trapero-Bertran; Álvaro Hidalgo-Vega
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807

Review 10.  Progressive realisation of universal health coverage: what are the required processes and evidence?

Authors:  R Baltussen; M P Jansen; L Bijlmakers; N Tromp; A E Yamin; O F Norheim
Journal:  BMJ Glob Health       Date:  2017-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.